Affinage

CD55

Complement decay-accelerating factor · UniProt P08174

Length
381 aa
Mass
41.4 kDa
Annotated
2026-04-28
100 papers in source corpus 25 papers cited in narrative 25 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CD55 (decay-accelerating factor, DAF) is a GPI-anchored complement regulatory glycoprotein that accelerates the decay of C3/C5 convertases through its short consensus repeat (SCR) domains—particularly SCR3—thereby protecting host cells from autologous complement attack; biallelic loss-of-function mutations cause uncontrolled complement deposition on lymphocytes, leading to the CHAPLE syndrome of protein-losing enteropathy (PMID:28657829, PMID:7511675). Beyond complement regulation, CD55 serves as a multifunctional surface receptor: it is the cellular attachment factor for echoviruses, enterovirus 70, and coxsackievirus B3 (engaging SCR2–SCR3) (PMID:7517044, PMID:8764022, PMID:9601501), a ligand for the adhesion receptor CD97 (via SCR1) whose interaction promotes leukocyte adhesion and joint inflammation (PMID:9064337, PMID:20131275), and an essential erythrocyte surface determinant required for P. falciparum invasion (PMID:25954012). In a complement-independent context, lipid raft–localized CD55 activates ROR2/JNK and LCK signaling pathways to drive cancer stem cell self-renewal and chemoresistance, while its surface abundance is regulated transcriptionally by HIF under hypoxia, by EGFR/Wnt/β-catenin–LINC00973–miR-216b axis in tumors, and post-translationally by ST3GAL1-mediated O-sialylation that enhances complement-protective activity (PMID:28838952, PMID:15923405, PMID:36271172, PMID:33177111).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 1991 Medium

    Whether GPI-anchored complement regulators participate in signaling complexes was unknown; co-immunoprecipitation of CD55 and CD59 with an 80-kDa glycoprotein bearing kinase activity established that CD55 resides in detergent-resistant complexes with signaling potential.

    Evidence Co-immunoprecipitation from HPB-ALL cell lysates with kinase activity assay

    PMID:1715364

    Open questions at the time
    • Single co-IP without reciprocal validation or identification of the 80-kDa partner
    • No downstream signaling pathway delineated
    • Functional consequence of kinase activity not tested
  2. 1994 High

    The question of whether CD55 has functions beyond complement regulation was answered when it was identified as the cellular receptor for multiple echovirus serotypes, with GPI-anchored presentation essential for virus binding.

    Evidence Anti-DAF mAb blocking, PI-PLC treatment, and gain-of-function DAF-transfected CHO cell binding assay

    PMID:7517044

    Open questions at the time
    • Viral entry mechanism downstream of CD55 binding not resolved
    • Whether CD55 serves as entry receptor versus attachment receptor not distinguished
  3. 1994 Medium

    Mapping of complement-regulatory activity to SCR3 established the structural basis for decay-accelerating function and separated it from the GPI anchor's potential signaling role.

    Evidence Domain analysis and functional complement assays

    PMID:7511675

    Open questions at the time
    • Mechanistic signaling link through the GPI anchor inferred but not directly demonstrated
    • Structural basis of SCR3 interaction with convertases not resolved at atomic level
  4. 1996 High

    CD55 was identified as the ligand for the seven-span transmembrane receptor CD97, mapping the interaction to SCR1 and establishing a cell adhesion function distinct from complement regulation and virus binding.

    Evidence Cell adhesion assay with CD97-transfected COS cells, anti-SCR1 blocking mAb, and CD55-null erythrocytes from PNH/Inab patients

    PMID:9064337

    Open questions at the time
    • Downstream signaling through CD97 upon CD55 engagement not characterized
    • In vivo physiological consequence of the interaction not tested at this point
  5. 1996 High

    Extension of CD55's virus receptor role to enterovirus 70 demonstrated that diverse picornaviruses convergently exploit CD55 for cell entry.

    Evidence mAb blocking and gain-of-function DAF-transfected NIH 3T3 cells conferring EV70 susceptibility

    PMID:8764022

    Open questions at the time
    • Molecular determinants on CD55 engaged by EV70 not mapped at domain level
  6. 1998 High

    CVB3 was shown to use CD55 SCR2–SCR3 for attachment, and the CD97 EGF domain requirements for CD55 binding were mapped, together defining two distinct interaction surfaces on CD55.

    Evidence Anti-DAF domain-specific mAb blocking for CVB3; EGF domain deletion mutants and Ca²⁺ chelation for CD97 binding

    PMID:9601501 PMID:9603477

    Open questions at the time
    • Whether CVB3 requires a coreceptor for entry not resolved
    • Structural basis of CD55 SCR engagement by virus versus CD97 not compared
  7. 1999 High

    Cloning of mouse DAF isoforms (GPI-anchored and transmembrane) and demonstration that both protect cells from complement confirmed conservation and showed the CD97–CD55 interaction is species-restrictive.

    Evidence Stable transfection of GPI and TM isoforms in CHO cells with C3b deposition and hemolytic assays; DAF KO mouse erythrocyte adhesion assay

    PMID:10417349 PMID:10540231

    Open questions at the time
    • Physiological role of the TM isoform versus GPI isoform not distinguished in vivo
    • Species restriction mechanism not structurally explained
  8. 2002 High

    Two studies established CD55's role in the tumor microenvironment: DAF-using echovirus entry occurs through lipid rafts in a cholesterol-dependent manner, and VEGF-induced CD55 in the extracellular matrix is released by MMP-7 as a functional soluble complement inhibitor.

    Evidence Lipid raft fractionation and pharmacological inhibition for EV11 entry; VEGF treatment of HUVECs and MMP-7 release assay with complement functional readout

    PMID:12186914 PMID:12445304

    Open questions at the time
    • Whether raft localization of CD55 is required for all enterovirus serotypes not tested
    • In vivo relevance of MMP-7-released soluble CD55 not demonstrated
  9. 2003 High

    CD55 was shown to be a component of the LPS receptor complex, with direct lipid A binding triggering NF-κB translocation and MAP kinase activation, expanding CD55's role to innate immune signaling.

    Evidence CHO cell transfection with NF-κB reporter, co-IP of CD55–lipid A, FRET in human monocytes, MAP kinase phosphorylation assays

    PMID:12731067

    Open questions at the time
    • Whether CD55 signals independently of TLR4 or functions only as a co-receptor not resolved
    • Stoichiometry of CD55 in the LPS receptor complex unknown
  10. 2005 High

    Hypoxia-induced CD55 expression via a HIF-responsive promoter element was shown to promote apical neutrophil clearance from mucosal epithelia, linking tissue oxygen sensing to complement regulation at inflamed surfaces.

    Evidence Hypoxia gene expression screen, promoter-reporter with HIF site mutation, CD55 overexpression and PMN clearance assay with peptide mimetic blocking

    PMID:15923405

    Open questions at the time
    • Identity of the PMN surface receptor engaging CD55 during clearance not defined
    • Whether HIF1α or HIF2α drives CD55 induction not distinguished
  11. 2010 High

    Genetic deletion of CD55 in two independent arthritis models unexpectedly attenuated rather than exacerbated disease, establishing that the CD55–CD97 adhesion axis promotes joint inflammation in vivo.

    Evidence CD55 KO and CD97 KO mice in collagen-induced and K/BxN serum-transfer arthritis, clinical scoring, immunohistochemistry

    PMID:20131275

    Open questions at the time
    • Downstream signaling through CD97 in synoviocytes/macrophages not characterized
    • Whether complement-regulatory loss in KO mice partially counteracts the anti-inflammatory effect not assessed
  12. 2013 High

    HCV was found to upregulate CD55 transcription via core protein–driven CREB/SP-1 promoter activation and to physically incorporate CD55 into virion particles, establishing virus-directed exploitation of CD55 for complement evasion.

    Evidence Promoter-reporter mutagenesis, sucrose gradient co-purification of CD55 with HCV, anti-CD55 blocking infection assay

    PMID:23658447

    Open questions at the time
    • Whether CD55 incorporation into HCV particles is passive or actively selected not determined
  13. 2015 High

    A forward genetic screen identified CD55 as an essential host factor for P. falciparum erythrocyte invasion, demonstrating that CD55-null red blood cells are refractory to parasite attachment.

    Evidence Forward genetic screen using cultured CD55-null erythrocytes derived from hematopoietic stem cells, parasite invasion assay

    PMID:25954012

    Open questions at the time
    • Parasite ligand that engages CD55 not identified
    • Whether CD55's role is direct binding or membrane organization not resolved
  14. 2016 High

    Two discoveries revealed virus-directed CD55 exploitation: PIV5 incorporates functional CD55 into virions conferring complement resistance, and HCV infection induces a secreted CD55 splice isoform (sCD55) that inhibits C3 convertase in the extracellular milieu.

    Evidence Complement neutralization assay with PIV5 virions; RT-PCR for sCD55 isoform and C3 convertase/cytolysis assays with conditioned medium

    PMID:27357152 PMID:27505156

    Open questions at the time
    • Splicing regulatory mechanism for sCD55 generation not defined
    • Whether sCD55 and virion-incorporated CD55 differ functionally not compared
  15. 2017 High

    Biallelic CD55 loss-of-function mutations were shown to cause CHAPLE syndrome with uncontrolled complement activation on T cells, and separately, complement-independent lipid raft–localized CD55 was found to activate ROR2/JNK and LCK pathways driving cancer stem cell self-renewal and chemoresistance.

    Evidence Whole-exome sequencing with functional rescue for CHAPLE; transcriptomic comparison of CSC/non-CSC with lipid raft fractionation, ROR2/JNK and LCK inhibition for cancer signaling

    PMID:28657829 PMID:28838952

    Open questions at the time
    • How CD55 activates ROR2 in the absence of complement ligands not mechanistically resolved
    • Whether CHAPLE disease severity correlates with residual CD55 activity not studied across genotypes
  16. 2020 High

    ST3GAL1-mediated O-sialylation was shown to modulate CD55's complement-protective function, with disialylated core 2 O-glycans required for full inhibition of C3 deposition on cancer cells.

    Evidence ST3GAL1 siRNA knockdown, tandem mass spectrometry of CD55 glycans, C3 deposition and complement lysis assays in breast cancer cells

    PMID:33177111

    Open questions at the time
    • Which specific O-glycosylation sites on CD55 are critical not mapped
    • Whether sialylation affects CD55's non-complement functions (CD97 binding, virus receptor) not tested
  17. 2022 High

    An EGFR/Wnt/β-catenin–LINC00973–miR-216b regulatory axis was shown to upregulate CD55 in lung cancer, suppressing both complement activation and CD8⁺ T cell responses; combined anti-CD55/CD59 with anti-PD-1 produced synergistic tumor inhibition.

    Evidence β-catenin ChIP, miRNA sponging assay, LINC00973 promoter mutation, anti-CD55/CD59 antibody with complement and T cell activation assays, in vivo tumor growth

    PMID:36271172

    Open questions at the time
    • Whether this regulatory axis operates in cancer types beyond lung cancer not tested
    • Direct contribution of CD55 versus CD59 to immune evasion not individually quantified in the combination treatment

Open questions

Synthesis pass · forward-looking unresolved questions
  • The parasite ligand engaging CD55 during P. falciparum invasion remains unidentified, the structural basis of CD55's complement-independent signaling through ROR2 is unresolved, and whether post-translational modifications (sialylation, GPI remodeling) differentially regulate CD55's distinct functions (complement regulation, CD97 binding, virus entry, parasite attachment) has not been systematically addressed.
  • P. falciparum ligand for CD55 unknown
  • Atomic-resolution structure of CD55 in complex with C3 convertase not available
  • Systematic comparison of glycan requirements across CD55's multiple functions not performed

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 6 GO:0001618 virus receptor activity 3 GO:0098631 cell adhesion mediator activity 3 GO:0048018 receptor ligand activity 2
Localization
GO:0005886 plasma membrane 10 GO:0005576 extracellular region 2 GO:0031012 extracellular matrix 1
Pathway
R-HSA-168256 Immune System 6 R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 2
Partners
CD59CD97LCKROR2ST3GAL1TLR4
Complex memberships
LPS receptor complex

Evidence

Reading pass · 25 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1996 CD55 (DAF) was identified as the cellular ligand for the seven-span transmembrane receptor CD97; the interaction was mapped to the NH2-terminal short consensus repeat (SCR) of CD55, and erythrocytes lacking CD55 (from PNH or Inab phenotype patients) failed to adhere to CD97 transfectants, establishing specificity. Cell adhesion assay with CD97-transfected COS cells, blocking mAb against CD55 SCR1, and CD55-null erythrocytes as negative controls The Journal of experimental medicine High 9064337
1994 CD55 (DAF) functions as the receptor mediating attachment and infection by multiple echovirus serotypes; anti-DAF mAbs blocked echovirus 7 attachment, phospholipase C treatment (removing GPI-anchored proteins) abolished binding, and CHO cells expressing human DAF gained the ability to bind echovirus. Anti-DAF mAb blocking assay, phosphatidylinositol-specific phospholipase C treatment, and DAF-transfected CHO cell binding assay Proceedings of the National Academy of Sciences of the United States of America High 7517044
1996 CD55 (DAF) is the HeLa cell receptor for Enterovirus 70 (EV70); a blocking mAb (EVR1) directed against CD55 inhibited EV70 binding and infection, and stable expression of human DAF in NIH 3T3 cells conferred susceptibility to EV70 replication. mAb blocking assay, immunoprecipitation identifying ~75 kDa GPI-anchored glycoprotein, and stable DAF-transfected cell infection assay Journal of virology High 8764022
1998 The CD55-binding site on CD97 requires at least three tandemly linked EGF domains; deletion mutants of CD97 lacking individual EGF domains abolished CD55 binding, and mAbs against EGF domain 1 and removal of Ca2+ (required by EGF2 and EGF5 binding sites) blocked the interaction. Larger CD97 isoforms with additional EGF domains had significantly lower affinity for CD55, indicating that alternative splicing regulates ligand specificity. EGF domain deletion mutants in binding assay, mAb blocking, Ca2+ chelation experiments European journal of immunology High 9603477
1991 CD55 and CD59 co-immunoprecipitate with a common 80-kDa glycoprotein and (glyco)lipids in detergent-resistant complexes, and these complexes contain an associated protein kinase activity, suggesting CD55 is part of a GPI-anchored signaling complex. Co-immunoprecipitation from detergent lysates of HPB-ALL cell line, SDS-PAGE analysis, protein kinase activity assay Journal of immunology Medium 1715364
1994 CD55's complement regulatory activity is mediated through its third short consensus repeat (SCR3), and the GPI anchor connects CD55 with associated tyrosine kinases on the inner leaflet, enabling signaling in addition to complement decay acceleration. Structural domain analysis, functional complement assays, and review of biochemical fractionation studies The Journal of laboratory and clinical medicine Medium 7511675
1999 Mouse CD55 (both GPI-anchored and transmembrane isoforms) inhibits C3b deposition and protects cells from complement lysis; CD55 knockout mouse erythrocytes failed to adhere to mouse CD97 transfectants, and the CD97–CD55 interaction is species-restrictive (human erythrocytes did not bind mouse CD97). Stable transfection of DAF isoforms in CHO cells, C3b deposition assay, haemolytic assay, adhesion assay with DAF knockout mouse erythrocytes Immunology High 10540231
1999 Multiple mouse DAF isoforms generated by alternative splicing (from two genes Daf-GPI and Daf-TM) were identified; both TM and GPI-anchored forms were stably expressed in CHO cells and conferred protection from C3b deposition and complement-mediated lysis, demonstrating functional activity of distinct isoforms. Molecular cloning, Northern blot, stable transfection in CHO cells, C3b deposition assay, cell lysis assay, soluble recombinant DAF haemolytic inhibition assay The Biochemical journal High 10417349
1998 Cardiovirulent coxsackievirus B3 (CVB3) uses CD55 as an attachment receptor on HeLa cells; anti-DAF mAbs directed against SCR2 and SCR3 most effectively blocked binding and infection, and virus binding was associated with CD55 downregulation at the cell surface. CVB3 did not interact with structurally related complement regulators CD35, CD46, Factor H, or C4BP. Anti-DAF mAb blocking, phospholipase C treatment to remove GPI-anchored proteins, flow cytometry of CD55 surface expression, competitive binding assays Virology High 9601501
2002 A DAF-using echovirus 11 (EV11) strain enters cells via lipid rafts in a cholesterol- and cytoskeleton-dependent manner. DAF usage by EV11 enables the virus to associate with lipid raft components (Triton X-100 resistant fractions), and this raft-dependent entry pathway is post-binding but prior to RNA uncoating. Pharmacological inhibitors of endocytosis pathways, RNA transfection and virus-binding assays, confocal microscopy, co-purification of virus with lipid raft fractions after Triton X-100 extraction Journal of virology High 12186914
2005 CD55 expression is induced by hypoxia on the apical membrane of mucosal epithelial cells via a HIF binding site in the CD55 promoter (~200 bp region), and overexpression of CD55 in non-hypoxic epithelia promotes apical clearance of neutrophils; peptide mimetics of the PMN-binding site on CD55 blocked this clearance. Hypoxia gene expression screen, CD55 mRNA/protein induction assay, CD55 transfection in normoxic cells, PMN clearance assay, peptide mimetic blocking, promoter-reporter assay with HIF binding site mutation FASEB journal High 15923405
2003 CD55 is part of the LPS receptor complex and contributes to LPS signaling; CD55 transfection in CHO cells conferred NF-κB translocation after LPS/lipid A stimulation, co-immunoprecipitation showed CD55–lipid A interaction, FRET demonstrated CD55–lipid A proximity in human monocytes, and LPS-induced clustering of CD55 with CD11/CD18 was observed. MAP kinase pathways (p38, JNK, ERK) are activated downstream and can be blocked at TLR4. CHO cell transfection with human CD55, NF-κB reporter assay, co-immunoprecipitation with anti-lipid A mAb, FRET analysis in human monocytes, MAP kinase phosphorylation assays, TLR4 inhibition European journal of immunology High 12731067
2010 Deletion of CD55 in mouse models of rheumatoid arthritis (collagen-induced and K/BxN serum-transfer models) resulted in decreased arthritis rather than the disease aggravation seen in other inflammatory models, indicating that CD55–CD97 interaction on synoviocytes/macrophages promotes joint inflammation. CD55 knockout and CD97 knockout mice in two arthritis models, clinical scoring, immunohistochemistry Arthritis and rheumatism High 20131275
2015 CD55 is an essential host factor required for P. falciparum invasion of erythrocytes; CD55-null red blood cells derived from hematopoietic stem cells were refractory to invasion by all P. falciparum isolates tested because parasites failed to properly attach to the erythrocyte surface. Forward genetic screen using cultured RBCs from hematopoietic stem cells, CD55-null erythrocytes in parasite invasion assay Science High 25954012
2017 Biallelic loss-of-function mutations in CD55 cause loss of CD55 expression, leading to increased complement activation with surface deposition of complement and generation of soluble C5a on T lymphocytes, defective costimulatory function, and defective cytokine modulation. Genetic reconstitution of CD55 or treatment with a complement-inhibitory antibody reversed abnormal complement activation. Whole-exome sequencing, flow cytometry of complement deposition, complement activation assays on patient T lymphocytes, exogenous CD55 expression rescue, complement-inhibitory antibody rescue The New England journal of medicine High 28657829
2017 CD55 regulates cancer stem cell self-renewal and cisplatin resistance in a complement-independent manner via lipid raft localization; CD55 activates ROR2/JNK signaling to control self-renewal and core pluripotency genes, and in parallel activates LCK (lymphocyte-specific protein tyrosine kinase) signaling to induce DNA repair genes and cisplatin resistance. Comparative CSC/non-CSC transcriptomic analysis, lipid raft fractionation, ROR2/JNK pathway inhibition, LCK inhibition with saracatinib, KD/KO with self-renewal and chemoresistance phenotype readouts The Journal of experimental medicine High 28838952
2013 HCV infection upregulates CD55 expression on hepatocytes via HCV core protein-mediated enhancement of CD55 promoter activity dependent on CREB and SP-1 binding sites; IL-6 further augments this induction. CD55 associates with HCV particles purified by sucrose density gradient, and CD55-blocking antibodies with complement inhibited HCV infection. CD55 mRNA/protein assay in HCV-infected hepatocytes, luciferase-based promoter activity assay with CREB/SP-1 site mutation, sucrose density gradient ultracentrifugation of HCV particles, polyclonal anti-CD55 capture of HCV, blocking antibody infection assay Journal of virology High 23658447
2016 HCV infection induces synthesis of a secreted CD55 isoform (sCD55) via alternative splicing; conditioned medium from HCV-infected cells inhibits C3 convertase activity and complement-dependent cytolysis in a CD55-dependent manner, implicating sCD55 in complement evasion in the infected microenvironment. RT-PCR for sCD55 isoform, C3 convertase activity assay with conditioned medium, complement-dependent cytolysis assay, CD55-blocking antibody reversal Journal of immunology Medium 27357152
2020 ST3GAL1-mediated O-linked sialylation of CD55 protects cancer cells from complement-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity; ST3GAL1 silencing shifted CD55 O-glycan profile from disialylated core 2 to nonsialylated/monosialylated forms, increasing C3 deposition on breast cancer cells. ST3GAL1 siRNA knockdown, tandem mass spectrometry of N- and O-linked oligosaccharides released from CD55, C3 deposition assay, complement-mediated lysis assay, ADCC assay Cancer immunology research High 33177111
2012 Activation of dsRNA sensors TLR3, MDA5, and RIG-I in fibroblast-like synoviocytes upregulates CD55 expression, which enhances the capacity of fibroblasts to bind CD97-loaded beads; this upregulation was blocked by anti-CD55 antibodies, linking innate immune dsRNA sensing to the CD55–CD97 adhesion axis. Cytokine/TLR ligand stimulation of FLS, flow cytometry of CD55 expression, CD97-loaded bead binding assay, anti-CD55 antibody blocking PloS one Medium 22590509
2007 Neurosteroids progesterone and allopregnanolone enhance CD55 production following brain contusion injury in rats, suggesting that steroid-mediated induction of CD55 is a mechanism by which these steroids reduce complement convertase activity and neuroinflammation. Rat cortical contusion model, CD55 protein quantification after progesterone/allopregnanolone treatment Neuroscience letters Low 17826908
2010 Recombinant human CD55 (DAF) protects primary cultured neuronal cells from chemical hypoxia by inhibiting complement activation (reducing C3a accumulation and MAC formation) and by decreasing activated Src kinase (pTyr416-Src), caspase-9, and caspase-3 activity, reducing neuronal apoptosis and dendritic spine loss. Primary cortical neuron culture, NaCN hypoxia model, recombinant DAF treatment, TUNEL assay, MTT assay, dendritic spine counting, immunofluorescence for complement components and MAC, Western blot for activated caspases and Src Journal of neuroinflammation Medium 20380727
2002 CD55 is overexpressed on tumor cells and is upregulated on endothelial cells by VEGF at the cell surface and in the extracellular matrix (ECM); MMP-7 releases intact, functionally active CD55 from ECM (unlike papain which degrades it or collagenase which fails to release it), suggesting a role for soluble CD55 in protecting tumor microenvironment from complement. VEGF treatment of HUVEC cells, immunoassay of cell surface and ECM CD55, metalloproteinase treatment assays, functional complement assay of released CD55 Tissue antigens Medium 12445304
2022 EGFR/Wnt/β-catenin signaling induces lncRNA LINC00973 expression, which sponges CD55-targeting miR-216b, resulting in upregulated CD55 expression that suppresses complement activation and CD8+ T cell activation in lung cancer; anti-CD55/CD59 antibody treatment or LINC00973 promoter mutation activated complement and CD8+ T cells, and combined anti-CD55/CD59 with anti-PD-1 showed synergistic tumor inhibition. β-catenin ChIP for LINC00973 promoter, miRNA sponging assay, LINC00973 promoter mutation, anti-CD55/CD59 neutralizing antibody, complement activation assay, CD8+ T cell activation assay, tumor growth assay Nature cancer High 36271172
2016 Parainfluenza virus 5 (PIV5) incorporates functional CD55 into virions, and virion-incorporated CD55 (but not CD46) confers high resistance to complement-mediated neutralization; PIV5 infection upregulates cell surface CD55 (further enhanced by TNF-α), and virus derived from cells with higher CD55 levels is more resistant to complement neutralization. Complement neutralization assay with virus containing CD55 alone, CD46 alone, or both, flow cytometry of CD55 surface levels, virus derived from cells with modulated CD55 levels Virology High 27505156

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2012 TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. Cell metabolism 516 22560223
2003 Transcriptional outputs of the Caenorhabditis elegans forkhead protein DAF-16. Aging cell 331 12882324
2000 daf-12 encodes a nuclear receptor that regulates the dauer diapause and developmental age in C. elegans. Genes & development 316 10859169
1996 The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). The Journal of experimental medicine 285 9064337
2000 A transmembrane guanylyl cyclase (DAF-11) and Hsp90 (DAF-21) regulate a common set of chemosensory behaviors in caenorhabditis elegans. Genetics 284 10790386
1994 Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proceedings of the National Academy of Sciences of the United States of America 265 7517044
2013 PQM-1 complements DAF-16 as a key transcriptional regulator of DAF-2-mediated development and longevity. Cell 237 23911329
2002 The transporter classification (TC) system, 2002. Critical reviews in biochemistry and molecular biology 206 12449427
2005 Overlapping and distinct functions for a Caenorhabditis elegans SIR2 and DAF-16/FOXO. Mechanisms of ageing and development 205 16280150
1998 daf-12 regulates developmental age and the dauer alternative in Caenorhabditis elegans. Development (Cambridge, England) 203 9477318
2017 DAF-16/FOXO Transcription Factor in Aging and Longevity. Frontiers in pharmacology 183 28878670
2006 Worming pathways to and from DAF-16/FOXO. Experimental gerontology 160 16839734
2000 Reduction of Fe(III), Cr(VI), U(VI), and Tc(VII) by Deinococcus radiodurans R1. Applied and environmental microbiology 158 10788374
2006 The search for DAF-16/FOXO transcriptional targets: approaches and discoveries. Experimental gerontology 155 16934425
2010 A new DAF-16 isoform regulates longevity. Nature 154 20613724
2020 DAF-16/FoxO in Caenorhabditis elegans and Its Role in Metabolic Remodeling. Cells 153 31906434
2017 CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis. The New England journal of medicine 147 28657829
1994 Structure and function of decay accelerating factor CD55. The Journal of laboratory and clinical medicine 146 7511675
2013 Redox-dependent control of FOXO/DAF-16 by transportin-1. Molecular cell 134 23333309
2004 Sterol-derived hormone(s) controls entry into diapause in Caenorhabditis elegans by consecutive activation of DAF-12 and DAF-16. PLoS biology 127 15383841
2004 Environmentally induced foregut remodeling by PHA-4/FoxA and DAF-12/NHR. Science (New York, N.Y.) 125 15375261
1999 Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis and rheumatism 113 10211878
2002 A novel cell entry pathway for a DAF-using human enterovirus is dependent on lipid rafts. Journal of virology 108 12186914
2015 Malaria. A forward genetic screen identifies erythrocyte CD55 as essential for Plasmodium falciparum invasion. Science (New York, N.Y.) 103 25954012
1996 The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55). Journal of virology 103 8764022
1998 Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97. European journal of immunology 100 9603477
2012 Human CD55 expression blocks hyperacute rejection and restricts complement activation in Gal knockout cardiac xenografts. Transplantation 98 22391577
2007 Neurosteroids reduce inflammation after TBI through CD55 induction. Neuroscience letters 84 17826908
2006 Serotonin targets the DAF-16/FOXO signaling pathway to modulate stress responses. Cell metabolism 84 17141627
2006 The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. Autoimmunity reviews 84 17289551
2023 A review of chromium (Cr) epigenetic toxicity and health hazards. The Science of the total environment 79 37075992
2018 Beyond the Role of CD55 as a Complement Component. Immune network 79 29503741
1992 Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies. British journal of haematology 78 1384649
2010 Bioremediation of Cr(VI) and immobilization as Cr(III) by Ochrobactrum anthropi. Environmental science & technology 77 20608725
1991 Association of the CD59 and CD55 cell surface glycoproteins with other membrane molecules. Journal of immunology (Baltimore, Md. : 1950) 76 1715364
2017 CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. The Journal of experimental medicine 75 28838952
1992 Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas. British journal of cancer 71 1384641
2017 daf-16/FoxO promotes gluconeogenesis and trehalose synthesis during starvation to support survival. eLife 69 29063832
1998 Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor. Virology 67 9601501
1999 Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Immunology 63 10540231
2022 Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade. Nature cancer 62 36271172
2005 HIF-dependent induction of apical CD55 coordinates epithelial clearance of neutrophils. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 62 15923405
2021 Sulforaphane promotes C. elegans longevity and healthspan via DAF-16/DAF-2 insulin/IGF-1 signaling. Aging 60 33471780
1996 Identification of insect cell lines by DNA amplification fingerprinting (DAF). Insect molecular biology 55 8799737
2005 daf-7 and the development of Strongyloides ratti and Parastrongyloides trichosuri. Molecular and biochemical parasitology 54 15664656
1999 Protein carbonyl accumulation in aging dauer formation-defective (daf) mutants of Caenorhabditis elegans. The journals of gerontology. Series A, Biological sciences and medical sciences 52 10051850
2014 Transcriptional regulation of Caenorhabditis elegans FOXO/DAF-16 modulates lifespan. Longevity & healthspan 49 24834345
2020 Sialylation of CD55 by ST3GAL1 Facilitates Immune Evasion in Cancer. Cancer immunology research 48 33177111
2010 Deletion of either CD55 or CD97 ameliorates arthritis in mouse models. Arthritis and rheumatism 48 20131275
1999 Molecular and functional analysis of mouse decay accelerating factor (CD55). The Biochemical journal 47 10417349
2019 Effects of Lycium barbarum Polysaccharides on Health and Aging of C. elegans Depend on daf-12/daf-16. Oxidative medicine and cellular longevity 45 31583041
2014 Cell-nonautonomous effects of dFOXO/DAF-16 in aging. Cell reports 44 24508462
2015 The nuclear receptor DAF-12 regulates nutrient metabolism and reproductive growth in nematodes. PLoS genetics 43 25774872
2006 Complement decay accelerating factor (DAF)/CD55 in cancer. Cancer immunology, immunotherapy : CII 43 16485129
2006 Diminished expression of complement regulatory proteins (CD55 and CD59) in lymphocytes from systemic lupus erythematosus patients with lymphopenia. Lupus 41 17080916
2003 Deficiency of red cell bound CD55 and CD59 in patients with systemic lupus erythematosus. Immunology letters 41 12880676
2021 Neuronal DAF-16-to-intestinal DAF-16 communication underlies organismal lifespan extension in C. elegans. iScience 40 34235410
2010 Decay accelerating factor (CD55) protects neuronal cells from chemical hypoxia-induced injury. Journal of neuroinflammation 40 20380727
2004 Loss of CD55 is associated with aggressive breast tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 40 15102687
2014 Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer. Archives of pathology & laboratory medicine 39 24978917
2006 Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. Biochimica et biophysica acta 37 16784816
2003 CD55/decay accelerating factor is part of the lipopolysaccharide-induced receptor complex. European journal of immunology 35 12731067
1976 Macrophage requirements of CR- and CR+ B lymphocytes for antibody production in vitro. Journal of immunology (Baltimore, Md. : 1950) 35 1083874
2010 Expression of CD55 and CD59 on peripheral blood cells from systemic lupus erythematosus (SLE) patients. Cellular immunology 34 20727519
2000 Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies. European journal of haematology 34 10680700
2008 Terminal Continuation (TC) RNA amplification enables expression profiling using minute RNA input obtained from mouse brain. International journal of molecular sciences 32 19165351
2018 DAF-21/Hsp90 is required for C. elegans longevity by ensuring DAF-16/FOXO isoform A function. Scientific reports 29 30104664
2012 Triggering of the dsRNA sensors TLR3, MDA5, and RIG-I induces CD55 expression in synovial fibroblasts. PloS one 29 22590509
2006 C. elegans STAT cooperates with DAF-7/TGF-beta signaling to repress dauer formation. Current biology : CB 29 16401427
2004 Expression of CD97 and CD55 in human medullary thyroid carcinomas. International journal of oncology 29 14719104
2017 Human papillomavirus E6 protein enriches the CD55(+) population in cervical cancer cells, promoting radioresistance and cancer aggressiveness. The Journal of pathology 28 28944962
2016 Functional Conservation and Divergence of daf-22 Paralogs in Pristionchus pacificus Dauer Development. Molecular biology and evolution 28 27189572
2013 Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles. Journal of virology 28 23658447
2022 Lonicera japonica polysaccharides improve longevity and fitness of Caenorhabditis elegans by activating DAF-16. International journal of biological macromolecules 27 36586650
2002 The role of CD55 in protecting the tumour environment from complement attack. Tissue antigens 27 12445304
2023 Luteolin promotes pathogen resistance in Caenorhabditis elegans via DAF-2/DAF-16 insulin-like signaling pathway. International immunopharmacology 26 36640711
2015 The Deubiquitylase MATH-33 Controls DAF-16 Stability and Function in Metabolism and Longevity. Cell metabolism 26 26154057
2017 Neuronal functions of FOXO/DAF-16. Nutrition and healthy aging 25 28447066
2001 A DAF-1-binding protein BRA-1 is a negative regulator of DAF-7 TGF-beta signaling. Proceedings of the National Academy of Sciences of the United States of America 25 11353865
1977 Tc-99m methylene diphosphonate versus Tc-99m pyrophosphate: biologic and clinical comparison. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 25 197133
2008 Molecular cloning and DNA binding characterization of DAF-16 orthologs from Ancylostoma hookworms. International journal for parasitology 24 18930062
2005 Review: Cromer and DAF: role in health and disease. Immunohematology 24 15954803
2020 The precursor of PI(3,4,5)P3 alleviates aging by activating daf-18(Pten) and independent of daf-16. Nature communications 23 32901024
1994 Distribution of C3-step regulatory proteins of the complement system, CD35 (CR1), CD46 (MCP), and CD55 (DAF), in hematological malignancies. Leukemia & lymphoma 21 7514063
2021 Barley β-glucan resist oxidative stress of Caenorhabditis elegans via daf-2/daf-16 pathway. International journal of biological macromolecules 20 34798183
2017 Dianxianning improved amyloid β-induced pathological characteristics partially through DAF-2/DAF-16 insulin like pathway in transgenic C. elegans. Scientific reports 20 28900141
2008 Reduction of CD55 and/or CD59 in red blood cells of patients with HIV infection. Medical science monitor : international medical journal of experimental and clinical research 20 18443552
2016 Parainfluenza virus 5 upregulates CD55 expression to produce virions with enhanced resistance to complement-mediated neutralization. Virology 19 27505156
2012 Bacterial diversity in Cr(VI) and Cr(III)-contaminated industrial wastewaters. Extremophiles : life under extreme conditions 19 22258276
2001 Upregulation of DAF (CD55) on orbital fibroblasts by cytokines. Differential effects of TNF-beta and TNF-alpha. Current eye research 19 11840345
2018 MPK-1/ERK pathway regulates DNA damage response during development through DAF-16/FOXO. Nucleic acids research 18 29788264
2016 Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus. Journal of immunology (Baltimore, Md. : 1950) 18 27357152
2014 Cytogenomics of hexavalent chromium (Cr 6+) exposed cells: a comprehensive review. The Indian journal of medical research 18 24820829
1993 A monoclonal antibody against human decay-accelerating factor (DAF, CD55), D17, which lacks reactivity with semen-DAF. Immunology letters 18 7505002
2021 Phosphatidylcholine mediates the crosstalk between LET-607 and DAF-16 stress response pathways. PLoS genetics 17 34014977
2021 Characterization of the endogenous DAF-12 ligand and its use as an anthelmintic agent in Strongyloides stercoralis. eLife 17 34874004
2019 Bee Venom Alleviates Atopic Dermatitis Symptoms through the Upregulation of Decay-Accelerating Factor (DAF/CD55). Toxins 16 31027358
2017 Inhibitory effect of trans-caryophyllene (TC) on leukocyte-endothelial attachment. Toxicology and applied pharmacology 16 28624443
2011 Expression of complement regulatory proteins CD55, CD59, CD35, and CD46 in rheumatoid arthritis. Revista brasileira de reumatologia 16 21953001
2010 Toxic effects of Cr(VI) and Cr(III) on energy metabolism of heterotrophic Euglena gracilis. Aquatic toxicology (Amsterdam, Netherlands) 16 20851473